Program
bezisterim
Also written as “HE3286” and “NE3107”.
Its studies are mostly in Parkinson Disease · Insulin Resistance · Post-Acute COVID-19 Syndrome · Alzheimer Disease · Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Harbor Therapeutics | 50 open or running | phase 2since Feb 25, 2008 | Nov 6, 2007 | none ahead |
| BioVie | 40 open or running | phase 3since Dec 4, 2020 | Dec 4, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2007First study: phase 1 study in Insulin ResistanceNew to Harbor TherapeuticsHarbor Therapeutics · NCT00555451 · 66 enrolled · United States
- Feb 25, 2008Phase 2 study in Colitis, UlcerativeHarbor Therapeutics · NCT00628433 · 27 enrolled · United States
- Jun 6, 2008Phase 2 study in Diabetes Mellitus, Type 2Harbor Therapeutics · NCT00694057 · 164 enrolled · United States
- Jul 6, 2008Phase 2 study in Arthritis, RheumatoidHarbor Therapeutics · NCT00712114 · 14 enrolled · United States
- Oct 5, 2009Phase 1 study in Insulin ResistanceHarbor Therapeutics · NCT00991107 · 5 enrolled · United States
- Dec 4, 2020BioVie's first study: phase 3 study in Alzheimer DiseaseNew to BioVieBioVie · NCT04669028 · 439 enrolled · United States
- Sep 23, 2021Phase 2 study in Parkinson DiseaseBioVie · NCT05083260 · 46 enrolled · United States
- Dec 24, 2024Phase 2 study in Parkinson DiseaseBioVie · NCT06757010 · 57 enrolled · United States
- Feb 24, 2025Phase 2 study in Post-Acute COVID-19 SyndromeBioVie · NCT06847191 · 203 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06847191Post-Acute COVID-19 Syndrome · United States | 2 | Completed | BioVie | Aug 6, 2026 | 203 |
| NCT06757010Parkinson Disease · United States | 2 | Completed | BioVie | May 1, 2026 | 57 |
| NCT05083260Parkinson Disease · United States | 2 | Completed | BioVie | Nov 21, 2022 | 46 |
| NCT04669028Alzheimer Disease · United States | 3 | Completed | BioVie | Sep 30, 2023 | 439 |
| NCT00991107Insulin Resistance · United States | 1 | Completed | Harbor Therapeutics | Aug 2010 | 5 |
| NCT00712114Arthritis, Rheumatoid · United States | 2 | Completed | Harbor Therapeutics | Jul 2009 | 14 |
| NCT00694057Diabetes Mellitus, Type 2 · United States | 2 | Completed | Harbor Therapeutics | Jan 2010 | 164 |
| NCT00628433Colitis, Ulcerative · United States | 2 | Completed | Harbor Therapeutics | May 2009 | 27 |
| NCT00555451Insulin Resistance · United States | 1 | Completed | Harbor Therapeutics | Sep 2009 | 66 |
How it is read
Names in the registry
- “HE3286”, 7 entries
- “NE3107”, 4 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 2 studies
- Insulin Resistance, 2 studies
- Post-Acute COVID-19 Syndrome, 1 study
- Alzheimer Disease, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.